Compares two types of dialysis filters in adults with kidney failure on hemodialysis
Compares expanded and conventional dialysis filters in adults receiving hemodialysis for kidney failure.
Plain-language title generated from the registry record
Registry title: DIALysis With EXpanded Solute Removal
Key facts
- Where
- London, Orillia, and Ottawa, CanadaSee the 3 sites
Where in Canada
- London Health Sciences CentreLondon, CanadaTaking people
- Orillia Soldiers' Memorial HospitalOrillia, CanadaTaking people
- The Ottawa HospitalOttawa, CanadaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
- Trial code
- NCT06660277
- Record updated
- 24 September 2026
- Original description
The goal of this clinical trial is to evaluate the health effects of expanded hemodialysis in patients receiving hemodialysis. The main question it aims to answer is:Read full original descriptionShow less
DIALysis With EXpanded Solute Removal (DIALEX): A Large, Simple Randomized Trial to Evaluate the Major Health Effects of Expanded Versus Conventional Hemodialysis.
The goal of this clinical trial is to evaluate the health effects of expanded hemodialysis in patients receiving hemodialysis. The main question it aims to answer is:
1) Does expanded hemodialysis reduce the risk of death from any cause?
Researchers will compare expanded hemodialysis to conventional hemodialysis (the treatment currently used for the majority of patients receiving hemodialysis) to see if expanded hemodialysis works to improve patient outcomes.
Participants will continue to receive their regularly scheduled hemodialysis treatments using either a super high-flux/expanded dialysis filter or a high-flux/conventional dialysis filter. All other aspects of treatments remain the same. No additional tests or visits are required. Data will be obtained using administrative healthcare databases and medical record review (at a subset of participating locations).
Inclusion: One of:; Age 60 years or older; or; Age 45 to 59 years with a history of diabetes mellitus (Type 1 or Type 2) regardless of current glycemic status; and; Receiving any form of dialysis regularly for the previous 90 days; and; Currently receiving HD in-centre (main or satellite unit) 3 or more times per week; and; A valid provincial or territorial health insurance card number.
Exclusion: Not appropriate for this study in the opinion of the treating nephrologist or dialysis nurse practitioner due to any of:; Known or anticipated intolerance to the Nipro Elisio HX dialyzer; or; Planned to receive HDF; or; Planned to receive nocturnal HD; or; Anticipated to discontinue in-centre HD in the next 3 months for any reason (examples: palliation, transplantation, home dialysis, recovery of kidney function, death, others); or; Anticipated severe non-adherence to the frequency or duration of prescribed dialysis treatment; or; An overriding clinical preference for expanded HD (i.e., dialysis with the Elisio HX or other comparable dialyzer, such as Baxter TheranovaTM); or; Another medical, psychosocial, or logistical reason; or; Enrolled in another clinical trial that explicitly prohibits concurrent participation in other clinical trials or that would substantially interfere with adherence to the DIALEX procedures (note that DIALEX otherwise permits concurrent participation in other trials); or; Previously enrolled in this trial; or; Declined participation.